{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:13Z","timestamp":1791568813429,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jsat.2013.09.002","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T16:00:34Z","timestamp":1382544034000},"page":"390-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["A qualitative study of the adoption of buprenorphine for opioid addiction treatment"],"prefix":"10.1016","volume":"46","author":[{"given":"Carla A.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances L.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anadam","family":"Hilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Firemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance M.","family":"Weisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsat.2013.09.002_bb0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.15288\/jsad.2009.70.628","article-title":"Counselor attitudes toward pharmacotherapies for alcohol dependence","volume":"70","author":"Abraham","year":"2009","journal-title":"Journal of Studies on Alcohol and Drugs"},{"issue":"11","key":"10.1016\/j.jsat.2013.09.002_bb0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMp1108649","article-title":"Moving beyond parity\u2014Mental health and addiction care under the ACA","volume":"365","author":"Barry","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.jsat.2013.09.002_bb0015","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1377\/hlthaff.2011.0480","article-title":"The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act","volume":"30","author":"Buck","year":"2011","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.jsat.2013.09.002_bb0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: A consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implementation Science"},{"issue":"2","key":"10.1016\/j.jsat.2013.09.002_bb0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1037\/a0022284","article-title":"A guiding framework and approach for implementation research in substance use disorders treatment","volume":"25","author":"Damschroder","year":"2011","journal-title":"Psychology of Addictive Behaviors"},{"issue":"4","key":"10.1016\/j.jsat.2013.09.002_bb0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2006.05.021","article-title":"Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network","volume":"32","author":"Ducharme","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.09.002_bb0035","unstructured":"Friese, S. (2011). User's Manual for ATLAS.ti 6.0 Berlin: ATLAS.ti Scientific Software Development GmbH. Retrieved from http:\/\/www.atlasti.com\/uploads\/media\/atlasti_v6_manual.pdf."},{"key":"10.1016\/j.jsat.2013.09.002_bb0040","series-title":"Availability of addiction medications in private health plans","author":"Horgan","year":"2007"},{"key":"10.1016\/j.jsat.2013.09.002_bb0045","doi-asserted-by":"crossref","unstructured":"Knudsen, H. K., Abraham, A. J., & Roman, P. M. (2011). Adoption and implementation of medications in addiction treatment programs. J Addict Med, 5(1), 21\u201327. http:\/\/dx.doi.org\/10.1097\/ADM.0b013e3181d41ddb [doi].","DOI":"10.1097\/ADM.0b013e3181d41ddb"},{"key":"10.1016\/j.jsat.2013.09.002_bb0050","doi-asserted-by":"crossref","unstructured":"Knudsen, H. K., Ducharme, L. J., & Roman, P. M. (2007). The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 87(2\u20133), 164\u2013174. doi:S0376-8716(06)00305-X [pii]; http:\/\/dx.doi.org\/10.1016\/j.drugalcdep.2006.08.013 [doi].","DOI":"10.1016\/j.drugalcdep.2006.08.013"},{"key":"10.1016\/j.jsat.2013.09.002_bb0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/002204260503500308","article-title":"Organizational predictors of pharmacological innovation adoption: The case of disulfiram","volume":"35","author":"Knudsen","year":"2005","journal-title":"Journal of Drug Issues"},{"key":"10.1016\/j.jsat.2013.09.002_bb0060","doi-asserted-by":"crossref","unstructured":"Lynch, F., McCarty, D., Mertens, J., Perrin, N., Green, C., Parthasarathy, S. et al. (2013). (under review). Costs of care for persons with opioid dependence in two integrated health systems. Addiction Science and Clinical Practice.","DOI":"10.1186\/1940-0640-9-16"},{"key":"10.1016\/j.jsat.2013.09.002_bb0065","doi-asserted-by":"crossref","unstructured":"Mark, T. L., Kassed, C. A., Vandivort-Warren, R., Levit, K. R., & Kranzler, H. R. (2009). Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug and Alcohol Dependence, 99(1\u20133), 345\u2013349. doi:S0376-8716(08)00305-0 [pii]; http:\/\/dx.doi.org\/10.1016\/j.drugalcdep.2008.07.018 [doi].","DOI":"10.1016\/j.drugalcdep.2008.07.018"},{"key":"10.1016\/j.jsat.2013.09.002_bb0070","doi-asserted-by":"crossref","unstructured":"Mark, T. L., Levit, K. R., Vandivort-Warren, R., Buck, J. A., & Coffey, R. M. (2011). Changes In US spending on Mental Health And Substance Abuse Treatment, 1986\u20132005, and implications for policy. Health Affairs (Project Hope), 30(2), 284\u2013292. doi:30\/2\/284 [pii]; http:\/\/dx.doi.org\/10.1377\/hlthaff.2010.0765 [doi].","DOI":"10.1377\/hlthaff.2010.0765"},{"key":"10.1016\/j.jsat.2013.09.002_bb0075","doi-asserted-by":"crossref","unstructured":"Reif, S., Thomas, C. P., & Wallack, S. S. (2007). Factors determining how early adopter physicians use buprenorphine in treatment. J Addict Med, 1(4), 205\u2013212. http:\/\/dx.doi.org\/10.1097\/ADM.0b013e31814c3fa8 [doi];01271255-200712000-00006 [pii].","DOI":"10.1097\/ADM.0b013e31814c3fa8"},{"key":"10.1016\/j.jsat.2013.09.002_bb0080","doi-asserted-by":"crossref","unstructured":"Rieckmann, T., Daley, M., Fuller, B. E., Thomas, C. P., & McCarty, D. (2007). Client and counselor attitudes toward the use of medications for treatment of opioid dependence. Journal of Substance Abuse Treatment, 32(2), 207\u2013215. doi:S0740-5472(06)00307-2 [pii]; http:\/\/dx.doi.org\/10.1016\/j.jsat.2006.09.002 [doi].","DOI":"10.1016\/j.jsat.2006.09.002"},{"key":"10.1016\/j.jsat.2013.09.002_bb0085","series-title":"Diffusion of innovations","author":"Rogers","year":"2003"},{"key":"10.1016\/j.jsat.2013.09.002_bb0090","doi-asserted-by":"crossref","unstructured":"Savage, S. A., Abraham, A. J., Knudsen, H. K., Rothrauff, T. C., & Roman, P. M. (2012). Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages. Journal of Substance Abuse Treatment, 42(1), 16\u201324. doi:S0740-5472(11)00118-8 [pii]; http:\/\/dx.doi.org\/10.1016\/j.jsat.2011.06.009 [doi].","DOI":"10.1016\/j.jsat.2011.06.009"},{"key":"10.1016\/j.jsat.2013.09.002_bb0095","unstructured":"Substance Abuse and Mental Health Services Administration. (2012a). CSAT Buprenorphine Information Center. Retrieved from http:\/\/buprenorphine.samhsa.gov\/data.html."},{"key":"10.1016\/j.jsat.2013.09.002_bb0100","unstructured":"Substance Abuse and Mental Health Services Administration. (2012b). National Survey of Substance Abuse."},{"key":"10.1016\/j.jsat.2013.09.002_bb0110","series-title":"New treatments for addiction: Behavioral, ethical, legal and social questions","first-page":"140","article-title":"Adoption of drug abuse treatment technology in specialty and primary care settings","author":"Thomas","year":"2004"},{"issue":"8","key":"10.1016\/j.jsat.2013.09.002_bb0115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1176\/ps.2008.59.8.909","article-title":"Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists","volume":"59","author":"Thomas","year":"2008","journal-title":"Psychiatric Services"},{"issue":"1","key":"10.1016\/j.jsat.2013.09.002_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice. Adoption of naltrexone in alcoholism treatment","volume":"24","author":"Thomas","year":"2003","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2013.09.002_bb0125","doi-asserted-by":"crossref","unstructured":"Thomas, S. E., Miller, P. M., Randall, P. K., & Book, S. W. (2008). Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. Journal of Substance Abuse Treatment, 35(3), 260\u2013268. doi:S0740-5472(07)00348-0 [pii];http:\/\/dx.doi.org\/10.1016\/j.jsat.2007.11.001 [doi].","DOI":"10.1016\/j.jsat.2007.11.001"},{"key":"10.1016\/j.jsat.2013.09.002_bb0130","doi-asserted-by":"crossref","unstructured":"Wallack, S. S., Thomas, C. P., Martin, T. C., Chilingerian, J., & Reif, S. (2010). Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication. Journal of Behavioral Health Services & Research, 37(1), 64\u201378. http:\/\/dx.doi.org\/10.1007\/s11414-008-9132-4 [doi].","DOI":"10.1007\/s11414-008-9132-4"},{"issue":"9","key":"10.1016\/j.jsat.2013.09.002_bb0135","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s11606-008-0686-x","article-title":"Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers","volume":"23","author":"Walley","year":"2008","journal-title":"Journal of General Internal Medicine"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547213002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547213002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:40:24Z","timestamp":1760038824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547213002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0740547213002201"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2013.09.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A qualitative study of the adoption of buprenorphine for opioid addiction treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}